Background: Diagnostic tools to identify allergens that cause allergic symptom is important part in the care of allergic patients. Detection of causative allergen can be performed by in vivo skin prick test (SPT) or in vitro tests for detection serum specific immunoglobulin E (sIgE). The common methods used are fluorescent enzyme assay and immunoblotting assay.
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Introduction
Allergic diseases have been increasing around the world. To identify causative allergens is the important part of diagnosis and treatment. Detection of causative allergen by skin prick test (SPT) is commonly used because of the high sensitivity, 1, 2 rapidity and inexpensiveness. Allergen-specific immunoglobulin E (sIgE) blood assay offers the alternative tool to identify the causative allergen. The advantages of sIgE blood assay are the variety of assays including quantitative or semi-quantitative system, lack of medication/ skin condition interference and no risk of severe allergic reaction occurred during the assay.
Results
Study population
There were 202 participants, age from 1 month to 60 years (mean ± SD = 10.57 ± 14.13), in the study. Fifty-seven were male and 145 were female. One hundred and fifty nine participants age ≤ 17 years. The underlying allergic diseases were asthma (n = 9, 4.46%), allergic rhinitis and allergic rhino-conjunctivitis (n = 58, 28.71%), atopic dermatitis (n = 28, 13.86%), food allergy (n = 86, 42.57%), urticaria (n = 18, 8.91%) and anaphylaxis (n = 3, 1.49%).
Performance of Immunoblotting assay (Euroline) and Fluorescence enzyme assay (ImmunoCAP) compared with skin prick test
The performance of two vitro sIgE assays for each allergen was compared to the skin prick test as shown in Table 1 . Using the SPT cut-off mean wheal diameter of at least 3 millimeters and sIgE cut-off value (≥ 0.35 kUA/L) (class I), overall agreement of ImmunoCAP and SPT were 63.9-93.2% while the agreement of Euroline and SPT was 68.4-86.2%. When compared to SPT, both Euroline and ImmunoCAP displayed high sensitivity, specificity, PPV and agreement for Der p, Der f and crab sIgE detection. However, Euroline had lower sensitivity but higher specificity than ImmunoCAP for cat, dog and wheat sIgE detection (sensitivity 48.0%, 33.3%, 31.4 % and specificity 96.6%, 96.7%, 90.0%, respectively).
Recently, various commercial analytical system for sIgE detection have been developed for example radioimmunoas -say, chemiluminescence, enzyme-immunoassay, fluorescence/ enzyme-immunoassay and immunoblotting assay. Only few sIgE determination methods have been approved by United State Food and Drug Administration (US FDA) such as ImmunoCAP (Phadia, Uppsala, Sweden), Turbo RAST (Agilent Technologies Co, Santa Clara, California) and Immulite (Siemens Medical Solutions Diagnostics, Tarrytown, New York). Despite these systems provided the result in the same unit, the result is not always equivalent. 3, [8] [9] [10] Euroline (Euroimmun, Medizinische Labordiagnostika, AG, Germany), an IgE determination system using immunoblotting assay has some advantages such as the requirement of only small amount of sera, no automate machine requirement, minimal hands-on time, appropriate for screening multiple allergen and cost-saving. While ImmunoCAP (Phadia, Uppsala, Sweden), a fluorescence/enzyme-immunoassay, has some advantages such as high through-put with a lot of number of sample load per day but it has some disadvantage such as automate machine requirement and expensive. Nowadays, there has been no study to evaluate the performance of sIgE detection systems using immunoblotting assay compared to the widely-used in vivo SPT. Our study aimed to evaluate the performance of an immunoblot (Euroline) and a fluorescence/enzyme-immunoassay (ImmunoCAP) for the detection and quantitation of sIgE in comparison with in vivo SPT.
of a wheal with a mean wheal diameter of at least 3 millimeters (mm) greater than that elicited by the negative control accompanied by erythema. The mean of the largest and midpoint orthogonal diameters was designated as the mean wheal diameter (MWD).
Serum specific IgE assays
Serum samples were collected from the participants at the same visit as SPT, then divided into 2 aliquots and store at -20°C until use. The level of sIgE was quantified using fluorescence enzyme immunoassay (PharmaciaCAP, Pharmacia) and immunoblotting assay (Euroline, Medizinische Labordiagnostika AG) according to the manufacturer's instructions. SIgE for Der p, Der f, cat, dog, egg white, egg yolk, cow's milk, wheat, shrimp and food allergen components (gluten/omega-5 gliadin, ovalbumin, ovomucoid) were measured. Level of specific IgE ≥ 0.35 kUA/L (Class 1) was considered to be positive result for both assays.
Statistical analysis
The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of Euroline and ImmunoCAP were analyzed according to SPT for each allergen. The correlation of sIgE level and SPT as well as between Euroline and ImmunoCAP were analyzed using Spearman's rho correlation. A receiver-operating characteristic (ROC) curve analysis was performed to verify the performance of Euroline and ImmunoCAP with SPT. Agreement between sIgE and SPT was assessed by kappa statistics. b) The analysis at SPT cut-off 5 mm and class III sIgE 
Correlation between specific IgE measurement using Immuno-CAP and Euroline with SPT
The correlation of both sIgE assays and SPT was analyzed. 
Discussion
The diagnosis of IgE-mediated allergy is based on clinical symptoms and the evidence of sensitization. SPT is the primary tool for allergist in detection of the causative allergen. It is convenient, rapid, no machine requirement and inexpensive. However, the result of SPT may depend on the performers and can also be affected by medications while in vitro sIgE determination can overcome the disadvantage of SPT.
Currently, a number of in vitro sIgE determination systems are available. Each of them uses different allergen sources and distinct IgE detection system. Thus, the sIgE results measured by one system might not be interchangeable with the others. When compared the two sIgE determination systems to SPT, our results revealed that both Euroline and ImmunoCAP provided good to fair performance depending on types of allergens. For house dust mites (Der p and Der f), the excellent concordance has been identified between SPT and both sIgE determination systems. For other allergens except crab, Euroline performed with lower sensitivity but higher specificity compared to ImmunoCAP. Euroline also provided slightly higher agreement with SPT than ImmunoCAP for egg white and crab allergens. The discordance between sIgE and SPT demonstrated in our study is in line with previous reports demonstrating some discordance between sIgE and SPT. The discordance rates varied depending on type of allergens and patients' factors. 7, 11, 12 Chauveau et al demonstrated the good agreement between SPT and sIgE measured with Allergy Screen Test Panel (Mediwiss Analytic, Moers,Germany) for house dust mites and a poor agreement for cat, dog, alternaria, and grass pollen. 13 de Vos et al studied the concordance between SPT for 7 common aeroallergens (grass pollen, ragweed pollen, dust mite, cockroach, mouse, cat, and dog) and sIgE testing using Immulite 2000 3gAllergy
T system (Siemens AG, Munich, Germany) in 40 atopic inner-city children aged 18 to 48 months. The study revealed a fair correlation for most allergens and no correlation between SPT grade and sIgE level for dog. 14 The discrepancies of the result of SPT and sIgE assays in our study can be explained by the differences in composition of allergens used in SPT and sIgE assays as well as patients' factors.
When the two sIgE determination systems were compared, there was a significant correlation of the sIgE levels for most allergens. The correlation was strong for Der p, Der f and egg white but weak for dog. Interestingly, both Euroline and ImmunoCAP have good concordance in detection of sIgE for food allergen components.
When compared Euroline with ImmunoCAP by ROC analysis, there were some marginal discrepancies between both systems. ImmunoCAP revealed slightly higher accuracy in detection of sIgE to majority of allergens used in this study except cat and egg white. The discrepancies between both systems could be due to the differences in assay technique as well as the composition and concentration of allergens.
It is important to emphasize that a positive serum sIgE or SPT indicates a sensitization to an allergen and is not equivalent to a clinical diagnosis. This limitation highlights the need for the clinician to use medical history together with knowledge of the test characteristics to select and interpret tests properly.
To the best of our knowledge, our study has been the first to evaluate performance of Euroline, the system using immunoblotting technique and another system using fluorescence enzyme-immunoassay (ImmunoCAP) with SPT. Based on SPT, Euroline shows comparable performance with ImmunoCAP for several common allergens. Furthermore, the levels of sIgE detected by Euroline significantly correlated with those measured by ImmunoCAP. Interestingly, there was good concordance between the two systems in detecting sIgE for food allergen components. Therefore, our data suggested that Euroline provided high accuracy for several common allergens and food components. Since system of Euroline has some advantages as prior mentioned, further study with more allergens and the correlation with clinical data should be performed.
